Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pediatric blunt liver and spleen injury treated in hospitals with pediatric intensive care units: Post-hoc analysis of a multicenter, retrospective observational study.
Yamamoto R, Sato Y, Maeshima K, Tomita K, Takemura R, Katsura M, Kondo Y, Yasuda H, Kushimoto S, Sasaki J. Yamamoto R, et al. Among authors: yasuda h. J Pediatr Surg. 2024 Dec 16;60(3):162106. doi: 10.1016/j.jpedsurg.2024.162106. Online ahead of print. J Pediatr Surg. 2024. PMID: 39733604 Free article.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
Romosozumab versus bisphosphonates for preventing subsequent vertebral fractures after balloon kyphoplasty: comparison using data from two prospective multicenter studies.
Inose H, Takahashi S, Teraguchi M, Kato T, Yamada K, Yasuda H, Terakawa M, Minetama M, Tomori M, Nakagawa Y, Yoshii T. Inose H, et al. Among authors: yasuda h. JBMR Plus. 2024 Oct 29;9(1):ziae137. doi: 10.1093/jbmrpl/ziae137. eCollection 2025 Jan. JBMR Plus. 2024. PMID: 39664929 Free PMC article.
Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version).
Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. Shimada A, et al. Among authors: yasuda h. J Diabetes Investig. 2025 Jan;16(1):163-168. doi: 10.1111/jdi.14267. Epub 2024 Nov 12. J Diabetes Investig. 2025. PMID: 39529490 Free PMC article.
Effects of switching from MiniMed™ 640G to 770G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus.
Kogai T, Sato J, Yasuda H, Ayame T, Ozaki A, Takagi E, Koshibu M, Nishida Y, Ikeda F, Watada H. Kogai T, et al. Among authors: yasuda h. J Diabetes Investig. 2024 Nov 8. doi: 10.1111/jdi.14350. Online ahead of print. J Diabetes Investig. 2024. PMID: 39513544 Free article.
2,401 results